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Interstitial fluid pressure in intracranial tumours in
patients and in rodents
Y Boucher1, H Salehil*, B Witwerl*, GR Harsh 1V2 and RK Jain1
'Steele Laboratory, Department of Radiation Oncology and 2Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School,
Boston MA 02114, USA
Summary Fluid transport parameters in intracranial tumours influence the delivery of therapeutic agents and the resolution of peritumoral
oedema. The tumour and cortex interstitial fluid pressure (IFP) and the cerebrospinal fluid pressure (CSFP) were measured during the growth
of brain and pial surface tumours [R3230AC mammary adenocarcinoma (R3230AC) and F98 glioma (F98)] in rats. Intratumoral and
intracranial pressures were also measured in rodents and patients treated with dexamethasone, mannitol and furosemide (DMF), and
hypocapnia. The results show that (1) for the R3230AC on the pial surface, IFP increased with tumour volume and CSFP increased
exponentially for tumours occupying a brain volume of 5% or greater; (2) in F98 with volumes of approximately 10 mm3, IFP decreased from
the tumour to the cortex, whereas for tumour volumes > 16 mm3 IFP equilibrates between F98 and the cortex; (3) DMF treatment reduced the
IFP of intraparenchymal tumours significantly and induced a pressure gradient from the tumour to the cortex; and (4) in 11 patients with
intracranial tumours, the mean IFP was 2.0 ± 2.5 mmHg. In conclusion, the IFP gradient between intraparenchymal tumours and the cortex
decreases with tumour growth, and treatment with DMF can increase the pressure difference between the tumour and surrounding brain. The
results also suggest that antioedema therapy in patients with brain tumours is responsible in part for the low tumour IFP.
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Studies from our group and other investigators have shown that the
interstitial fluid pressure (IFP) of human tumours in situ is signifi-
cantly elevated compared with normal tissues (Boucher et al, 1991;
Roh et al, 1991; Gutmann et al, 1992; Less et al, 1992; Curti et al,
1993; Arbit et al, 1994; Nathanson and Nelson, 1994). In most
normal tissues the IFP is around 0 mmHg while for the different
carcinoma types measured to date the mean IFPs vary between 14
and 30 mmHg. In general, in human and experimental tumours the
IFP increases with tumour size (Jain, 1987a; Boucher et al, 1990,
1991, 1995; Gutmann et al, 1992; Lee et al, 1992; Nathanson and
Nelson, 1994). However, in other studies, the IFP was found to be
independent of the tumour volume (Less et al, 1992; Curti et al,
1993; Boucher et al, 1995; Tufto and Rofstad, 1995; Znati et al,
1996). Measurements in experimental tumours have demonstrated
that (1) the IFP is uniform throughout the centre of tumours and
drops steeply in the tumour periphery or in the normal tissue
surrounding the tumour (Boucher et al, 1990; Boucher and Jain,
1992; DiResta et al, 1993) and (2) that the hydrostatic and oncotic
pressures in the vascular and interstitial space are at or close to
equilibrium (Baxter and Jain, 1989, Boucher and Jain 1992;
Stohrer et al, 1995). The similarity in hydrostatic pressures
between the microvascular and interstitial space is thought to be a
major mechanism limiting the convective delivery of large thera-
peutic agents to solid tumours (Jain and Baxter, 1988).
In a recent study, Arbit et al (1994) measured, at craniotomy, the
IFP in brain tumours and in the cortex and found that the mean IFPs
were 7.0 and 0.8 mmHg respectively. In untreated patients with
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brain tumours, mean CSFP was found to vary between 24 and 33
mmHg (Kullberg and West, 1965; Miller and Leech, 1975; Alberti
et al, 1978). The lower pressures in the cortex and tumour are prob-
ably not due to pressure differences between the ventricles and the
parenchyma as, under normal conditions, CSFP and intra-
parenchymal IFP are similar (Poll et al, 1972; Wiig and Reed,
1983) and, in the case of brain lesions, intraparenchymal IFP is
similar or higher than CSFP (Reulen and Kreysch, 1973; Reulen et
al, 1977: Sundbarg et al, 1987). The low IFPin intracranial tumours
at craniotomy is probably due to the management ofpatients with
agents and procedures (e.g. dexamethasone, mannitol, furosemide
(DFM), hypocapnia and opening ofthe intracranial cavity) that can
lower the tumour IFP as well as the intracranial pressure.
The goals of the present study were: (1) to measure at cran-
iotomy the tumour and the surrounding brain IFP in patients
treated with DMF and hypocapnia (2) to characterize the parame-
ters that determine IFPs in tumours growing in the intracranial
cavity; (3) to measure the pressure gradients between the tumour
and the surrounding brain as a function oftumour size; and (4) to
determine the modifications in CSFP and intracranial tumour IFP
induced by DMF treatment and hypocapnia. To accomplish goals
2,3 and 4, the IFP was measured in two rat tumours [R3230AC
mammary adenocarcinoma (R3230AC) and F98 glioma (F98)]
implanted on the pial surface and in the brain parenchyma. In the
R3230AC implanted on the pial surface, the IFP was measured as
a function of tumour size, and the relationship between the
microvascular pressure (MVP) and IFP was determined. In F98
tumours in the brain parenchyma, the IFP gradients from the
tumour to the cortex were measured as a function of tumour size
and DMF treatment.
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MATERIAL AND METHODS
Animal protocol
Surgeryand tumourimplantation
Fisher rats (150-180 g) The animals were anaesthetized with a
mixture ofketamine and xylazine (100 mg and 10 mg kg-'). With a
dentist's drill, two 3-mm holes were made through the bone on
each side of the sagittal suture. The centre of the two holes was
located 2 mm from the sagittal suture and 2 mm caudate to the
coronal suture. In both openings the dura was removed. For pial
surface tumours apiece ofR3230AC orF98 tumour (1 x 1 x 1 mm)
from a donor animal was introduced on the left side and a plastic
cover slip was secured to the bone with cyanocrylate glue to close
the opening. The other opening was also closed with a cover slip
after introducing artificial CSF. Intraparenchymal tumours were
also implanted following the preparation of a 3-mm opening in the
bone at the same location as for pial surface tumours. Tumour
slurry was prepared from pieces of R3230AC or F98 tumours and
introduced into a Hamilton syringe linked to a 23-gauge needle.
With a stereotaxic device the tip ofthe 23-gauge needle was placed
2 mm below the pial surface, and 20 gl of tumour slurry was
injected. The opening was closed as previously described. To
measure CSFP, 1-mm depressions occupying three-quarters of
the bone thickness were drilled 1.5 mm from the sagittal suture and
0.5 mm caudate to the coronal suture.
As it was not possible to measure the microvascular pressure of
the superficial microvessels of pial tumours through the 3-mm
openings, an 8-mm opening was prepared over the two hemi-
spheres with a dentist's drill. The dura was removed, and after
introducing a piece of R3230AC the opening was closed with a
plastic cover slip. The cover slip was perforated with four holes
(diameter approximately 2 mm) and covered on one side with a
thin transparent plastic wrap. Another cover slip was glued over
the perforated cover slip.
Preparation ofanimals forIFP measurements
The animals were anaesthetized with chloral hydrate (300 mg
kg-') and placed on a heating pad to maintain the body temperature
between 36°C and 37°C. The left femoral artery was cannulated
for measurement of arterial pressure and blood gases. The left
femoral vein was cannulated for injection of saline, Evans blue or
lissamine green. The animals were connected to an artificial venti-
lator following tracheotomy, and Pavalon (0.2 mg kg-') was given.
All the IFP and MVP measurements were accepted as valid when
the mean arterial pressure was greater than 70 mmHg and the
Paco2 was between 30 and 45 mmHg.
IFPandMVPmeasurements
IFP was measured with the micropipette technology described
previously (Boucher et al, 1990; Boucher and Jain, 1992). In the
R3230AC on the pial surface, IFP was measured in four different
groups on day 6, 10, 14-15 and 17-20 after tumour implantation.
The cover slip was removed, and artificial CSF (35-37°C) was
superfused continuously on the tumour surface. In the smaller
tumours on days 6 and 10, IFP was measured in the centre of the
tumour at a distance of approximately 0.5-1.0 mm from the
tumour surface. In the day 14-15 and 17-20 groups with the
tumour thickness varying between 3.5 and 6.0 mm, only the IFP
measurements obtained at a distance 2 0.5 mm from the tumour
surface were used for data analysis. Following completion of the
IFP measurements in the tumour, CSFP was measured through the
1-mm opening over the ventricle with a blunt 26-gauge needle
connected to a pressure transducer. The thin layer of bone that
remained in the 1-mm hole was easily perforated by carefully
pushing the 26-gauge needle through the bone.
For measurement of MVP and IFP in the large windows, the
first cover slip was removed and small holes were punctured
through the transparent plastic wrap with a 30-gauge needle to
have access to the tumour with micropipettes. Larger holes
resulted in bulging of the tumour through the opening. MVP
was measured in vessels with diameters between 40 and 100 gm.
To verify that the tip of the micropipette was in the lumen of the
tumour vessels, fast green (0.5%) was infused via the micro-
pipette. MVP measurements were considered valid when the fast
green disappeared rapidly with blood flow following the infusion.
MVP was compared with the IFP measured at adistance . 0.5 mm
from the tumour surface.
Measurement in intraparenchymal tumours was done in
R3230AC with tumour volumes between 50 and 175 mm3 and in
F98 gliomas with volumes between 10 and 70 mm3. In both
tumour types, the IFP was measured with micropipettes in the
tumour and the surrounding brain.
Table 1 Mean tumour volume and pressures in control and treated animals
Tumour type and location n Tumour volume Tumour IFP (mmHg) Cortex IFP CSFP
F98 parenchymal
Small 4 10.0 ± 2.5 9.0+ 2.5c,d 6.0±1 .Oa.c 5.5 ± 1.5a,d
Large 4 29.0 ± 9.0 16.0± 6.0a 18.0± 10.Oa,b 12.5+ 5.5a,b
Large DMF treatment 4 30.0 ± 26.0 4.5 +2.0a,c,d 1.5 ± 1.0b,c - 0.5 + 1 .5b,c,d
F98 pial surface
Control 4 31.0 ± 18.5 17.5 ± 8.Oc - 7.0 ± 2.6a.c
DMF treatment 4 39.0 ± 22.0 16.0 ± 4.Oc - 1.5 ± 1 .5a,c
R3230AC parenchymal
Control 4 109.0 ± 43.0 25.0 ± 1O.Oa 21.0 ± 11 .0a 13.0 ± 5.0
DMF treatment 4 127.0 ± 50.0 6.0 ± 1.Oa 4.0 ± 1 .a 7.0 ± 2.5
R3230AC pial surface
Control 6 31.0 ± 21.0 19.5+ 7.0a,c - 10.0+ 4.5a,c
DMF treatment 6 35.0 ± 25.0 8.0 ± 3.0ac _ 4.5 ± 1 .5a,c
a,b P<0.05 from top to bottom. c,d P<0.05 from left to right.
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Figure 1(A) Effect of tumour volume on the tumour IFP and CSFP in rats
with R3230AC growing on the pial surface. Pressures represent the average
of four to five animals for each time point (day 6, 10, 15 and 17-20) after
tumour implantation. The increase in tumour pressure was linear with tumour
volume (y=0.218 x+ 7.973, r2 = 0.99). At small tumour volumes CSFP is
independent of tumour size, at larger tumour size the increase in CSFP
can be described by an exponential function (y=4.075 (10)0.007x r2 = 0.969).
O, Tumour IFP; * CSFP. (B) Relationship between MVP and IFP in
R3230AC located on the pial surface. The MVP was measured in superficial
tumour vessels of 40-100 ,um. As indicated by the line of equality, the IFP
and MVP are closely related (y=4.5357 + 0.79682x r2 = 0.872, Spearman
correlation P<.03)
Manipulation oftumourandcortex IFP, and CSFP
Animals with F98 and R3230AC tumours implanted on the pial
surface or in the parenchyma were treated with DMF. The animals
were treated once daily with dexamethasone (3 mg kg-', i.p.), and
for 3-4 days before the measurements. The last injection of
dexamethasone was given 3-4 h before the IFP was measured.
Mannitol (2.5 g kg-', at a rate of 0.25 ml min-' over a period of
10 min) was given first followed by furosemide (2 mg kg-') 15 min
later. The pressure measurements were carried out under
hypocapnia (Paco2: 23-30 mmHg). The IFP was first measured
with micropipettes 30-40 min after the start of mannitol infusion.
CSFP was measured after the micropipette measurements. After
the measurements, 2.0% Evans blue (0.2ml 100g-') or 2.0%
lissamine green (0.5 ml 0Og-1) was injected via the femoral vein.
The animals were killed 30 min following the injection of Evans
blue and 5 min after lissamine green. The tumours were removed,
and the tumour volume was estimated as V = (r/6) a x b2, where a
is the largest and b is the smallest diameter ofthe tumour.
Statistical analysis
The data arepresented as the mean ±standard deviation. Significant
differences between groups were determined by the Student's t-test
(P <0.05) or ANOVA. For an ANOVA with a P <0.05, differences
between groups were evaluated by the Bonferroni - Dunn multiple
comparison test (P <0.016). Datathat were notnormally distributed
were analysed with the Wilcoxon signed-rank test.
Human protocol
Pressures were measured in 11 neurosurgical patients undergoing
resection for intracranial tumours. Before surgery, all patients
had received dexamethasone (10 mg i.v.), mannitol (0.5 mg kg-'
i.v.) and furosemide (20 mg i.v.) to reduce brain swelling during
and after the opening of the intracranial cavity (Table 1). Hyper-
ventilation was used to keep Paco2 between 25 and 32 mmHg, and
systemic arterial pressure was maintained at 120-140 mmHg. IFP
was measured with the wick-in-needle technique (Boucher et al,
1991). The IFP in the tumours was measured following the
opening of the intracranial cavity and removal of the dura. In five
cases, IFP was also measured in the brain surrounding the tumour.
RESULTS
Measurements in rodents
To test if the opening of the intracranial cavity to the atmosphere
would induce changes in intratumoral pressure and CSFP, both
pressures were monitored following removal ofthe cover slip. The
pressures remained stable after removal ofthe cover slip.
Figure IA shows the change in tumour IFP and CSFP as a func-
tion of the tumour (R3230AC) volume on the pial surface. The
tumour volumes varied between 1.0 and 230 mm3, and to calculate
the mean tumour volume and IFP the tumours were grouped in
four different groups depending on the number of days after
tumour implantation (Figure IA). Tumour IFP increased with
tumour size, while CSFP was not changed by the smaller tumour
volumes but increased steeply at tumour volumes between 90 and
230 mm3, which represents approximately 5-13% of the brain
volume of a 200-g rat.
To assess the influence ofPaco2 on the tumour (R3230AC) IFP,
the IFP was measured before and after modification ofthe rate and
volume ofventilation in ten animals. In all the animals, there was a
decrease in tumour IFP which varied between 17% and 50% at
mean values ofPaco2, which decreased from 36±2.5 to 24.5 ±2.5
mmHg. The mean tumour IFP significantly decreased from 27 +
15 to 18 ± 10 mmHg. The influence of Paco2 on CSFP was also
evaluated in five animals with tumours. With an average decrease
in Paco2 from 35.5 ± 1.5 to 23.5 ± 3.5 mmHg, CSFP significantly
decreased from 31 ±29 to 17 ± 15 mmHg.
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Figure 2 Pressure profiles from F98 gliomas to the cortex in treated and
non-treated animals with small and large tumours. The data points represent
single IFP measurements and the dotted line indicates the tumour-cortex
interface. The IFP increased at 2.0-2.5 mm from the pial surface in a rat with
a tumour volume of 10 mm3. In another animal with a tumour volume of 30
mm3, the IFP increased at 1.0 mm or less from the pial surface. In contrast,
in a rat with a large tumour (tumour volume 70 mm3), treated with DMF and
hypocapnia, the IFP increased at 2.0-2.5 mm from the pial surface. *, F98
small; A, F98 Large; O, F98 Large DMF
In pial surface tumours in large windows, the MVP of superfi-
cial vessels was compared with the IFP in the central regions ofthe
tumours. The IFP was high and uniform in the tumour centre and
generally dropped to lower values at 0.5 mm or less from the
tumour surface. The IFP at 2 0.5 mm from the surface and the
MVP were closely related (Figure 1B). The comparison between
the MVP in superficial vessels and the central IFP assumes that the
MVP of superficial and central vessels are similar (Boucher and
Jain, 1992).
Treatment with DMF and hypocapnia induced a significant
decrease in the IFP ofR3230AC implanted on the pial surface. IFP
was 19.5 ± 7.0 mmHg in the control group and 8.0 ± 3.0 mmHg in
the treated group (Table 1). In F98 tumours on the pial surface, IFP
was similar in the control and treated groups. In animals with F98
and R3230AC tumours, the CSFP was significantly decreased by
DMF treatment and hypocapnia (Table 1).
The tumours implanted in the brain parenchyma were identified
by the blue coloration resulting from the intravenous injection of
lissamine green. In the F98 and R3230AC tumours implanted in
the parenchyma, the tumour-cortex interface was located at
1.5-2.0 mm from the pial surface. For the pressure measurements,
the micropipettes were introduced at depths of 3.5-4.0 mm from
the pial surface; the IFP was measured for 20-30 s at intervals of
200-400 ,um as the micropipette was retrieved to the pial surface.
Depending on the fluid communication between the tumour and
the micropipette, 3-8 IFP measurements were obtained thus
permitting the characterization of IFP profiles from the tumour to
the surrounding cortex. In animals with small F98 tumours
(approximately 10 mm3), the IFP (five out of seven pressure
profiles) generally increased within adistance of2.0-2.5 mm from
the pial surface, which corresponds to the tumour-cortex interface
orthe peripheral regions ofthe tumours (Figure 2). In two pressure
profiles, the IFP did not increase fromthe cortex to the tumour; the
IFP in the tumour and in the cortex were similar. This type of IFP
profile could be because ofthe location of the micropipette in the
tumour periphery or in the surrounding cortex. In larger F98
tumours with volumes between 16 and 36 mm3, all the IFPprofiles
were uniform except for the pressure increase at a distance of 1.0
mm or less from the pial surface (Figure 2). In contrast, in animals
treated with DMF and with tumour volumes between 13 and 70
mm3, IFP (eight out ofnine pressure profiles) increased at 2.0-2.5
mm from the pial surface (Figure 2). The IFP in the tumour and
cortex as well as the CSFP were significantly decreased by DMF
treatment and hypocapnia (Table 1).
In R3230AC implanted in the parenchyma, the tumour volumes
were largerthan the F98 gliomas in both the control (52-150 mm3)
and treated (61-174 mm3) groups. Similar to the larger F98
tumours, in animals with R3230AC, the IFP in the tumour and the
cortex were similar (Table 1). The IFP increased at less than 0.5
mm from the pial surface. In animals treated with DMF and
hypocapnia, the IFP (six out ofeight pressure profiles) increased at
2.0-2.5 mm from the pial surface. Compared with the control
group, DMF treatment and hypocapnia significantly reduced the
IFP in the tumour and in the surrounding brain and induced a non-
significantly decrease in CSFP (Table 1).
For all the intraparenchymal tumours, in orderto calculate mean
values ofIFP, IFPs at> 2.0 mm from the pial surface were used to
calculate the mean tumour IFP, whereas the mean IFPs in the
cortex were determined from IFP measurements at less than 2.0
mm from the pial surface. This definition of the border between
the tumour and the cortex was based on the location of the
tumour-cortex interface at 1.5-2.0 mm from the pial surface and
on the fact that, in animals with small F98 tumours or in animals
treated with DMF, the IFP increased at 2.0-2.5 mm from the pial
surface. The data were characterized by two types of analyses. In
the type 1 analysis, all the IFP measurements in the tumour and in
Table 2 Mean tumour volume and pressures in control and treated animals
Tumour type and location n Tumour volume Tumour IFP (mmHg) Cortex IFP CSFP
F98 parenchymal
Small 4 10.0 ±2.5 11.0+ 1.5c,d 6.0± 1.Oa,c 5.5+ 1.5a,d
Large 4 29.0 ± 9.0 16.0± 6.0a 18.0+ 1O.Oa,b 12.5+ 5.5a,b
Large DMF treatment 4 30.0 ± 26.0 5.5 + 2.5a.c.d 1 .5 + 1.0b,c -0.5 + 1.5b,d
R3230AC
Control 4 109.0 ± 43.0 25.0 ± 1O.Oa 21.0 ± 11 .a 13.0 ± 5.0
DMF treatment 4 127.0 ± 50.0 7.0 + 1.Qa.c 3.5 + 1 .a,c 7.0 ± 2.5
a,bp<0.05 from top to bottom. c,d P<0.05 from left to right.
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Table 3 Interstitial fluid pressure in human intracranial tumours
Sex/age Tumour Previous Interstitial fluid pressure
(years) type treatment
Tumour Brain
surrounding
tumour
M/30 R-Glioblastoma X 3.0 3.5
M/39 R-Glioblastoma X 1.5 2.5
F/51 Glioblastoma - 0.5 0.5
F/48 Astrocytoma - 9.5 1.5
Ff70 Meningioma - 1.5 -
M/48 R-Glioblastoma S,X 0.0 -
F/36 R-Glioblastoma S,X 1.0 3.0
M/49 Oligo/Astrocytoma - 2.5 -
F/30 R-Astrocytoma S,C,X 2.5 -
M/36 Ganglioglioma - 0.5 -
F/62 R-Astrocytoma X,C,S 2.0 -
Patients were treated with dexamethasone, mannitol and furosemide before
surgery. R, recurrent; X, radiation; C, chemotherapy; S, surgery.
the cortex were included. The type II analysis included all the IFP
profiles in the experimental groups with large F98 and R3230AC
tumours as well as the IFPprofiles that had an increasing IFP from
the cortex to the tumour in animals treated with DMF and
hypocapnia and animals with small F98 tumours. The exclusion of
the IFP profiles that did not show a pressure increase from the
cortex to the tumour was based on the possibility that the
micropipettes could have been located in the periphery of the
tumour or in the cortex surrounding the tumour. The type I and II
analyses are given, respectively, in Table 1 and 2. In general, there
was a good agreement between the results of the type I and II
analyses. The main difference was found in R3230AC tumours
treated with DMF. The type II analysis revealed that the IFP was
significantly higher in the tumour than in the cortex (Table 2).
With both types ofanalyses, there was a significant pressure differ-
ence between the tumour and the ventricle in animals with F98
tumours treated with DMF and hypocapnia, whereas, in animals
with R3230AC tumours that were treated with DMF and
hypocapnia, the CSFP and tumour IFP were similar (Table 1 and
2). There was no significant difference between the cortex IFP and
the CSFP in treated and non-treated animals with F98 and
R3230AC tumours. In general the cortex IFP was similar or higher
than the CSFP, except in treated animals with large R3230AC
tumours for which the CSFP was higher than the cortex IFP.
Following the intravenous injection oflissamine green both F98
and R3230AC became blue, thus demonstrating the absence of a
blood-tumour barrier in these two tumour types. The treated and
non-treated R3230AC and F98 tumours were also permeable to
albumin as indicated by Evans blue.
Measurements in patients
The IFP was measured in 11 patients with an astrocytoma,
glioblastoma, meningioma or ganglioglioma (Table 3). The IFP in
10 of 11 tumours varied between 0.0 and 3.0 mmHg. In one astro-
cytoma the IFP was 9.5 mmHg. The mean IFP was 2.0 ± 2.5
mmHg. In five cases, the IFP measured in the brain surrounding
the tumour varied between 0.5 and 3.5 mmHg. with a mean of2.0
± 1.0 mmHg (Table 3).
DISCUSSION
One of the goals of the present study was to characterize the para-
meters that influence the IFP in intracranial tumours. Similar to
peripheral tumours, the IFP in R3230AC on the pial surface
increased with tumour size (Jain, 1987a; Boucher et al, 1990,
1991, 1995; Gutmann et al, 1992; Lee et al, 1992; Nathanson and
Nelson, 1994). In R3230AC implanted on the pial surface, the
MVP and IFP were similar (Figure iB), thus suggesting that the
increase in IFP with tumour size was due to the increasing MVP. In
peripheral tumours as well as in tumours implanted on the pial
surface, the high vascular permeability (Jain, 1987b; Yuan et al,
1994, 1995) and the absence of a functional lymphatic circulation
(Taginawa et al, 1981) are probably responsible for the equilibra-
tion in oncotic and hydrostatic pressures between the microvas-
cular and interstitial space (Jain, 1987b; Boucher and Jain, 1992).
The equilibration of hydrostatic and oncotic pressures suggests
that the MVP is the main driving force for interstitial hypertension
and that modifications in arteriovenous pressure differences are
responsible for the increase in IFP with tumour size. Increases in
mean arterial pressure induced by angiotensin II as well as the arti-
ficial occlusion of the venous outflow of a tumour can signifi-
cantly increase the tumour IFP (Wiig and Gadeholt, 1985; Zlotecki
et al, 1993, 1995). Arteriovenous pressure modifications in the
cerebral microcirculation could also contribute to the increase in
tumour MVP and IFP, especially when the mass effect produced
by the tumour induces a steep increase in CSFP (Figure IA). It has
been demonstrated that the cerebral venous pressure (CVP)
increases in parallel with the CSFP and it is always kept slightly
higher than the CSFP. Parallel modifications in CSFP and CVP
can be induced by the inflation of intracranial balloons or by the
modification of the PaCO2 (Yada et al, 1973; Luce et al, 1982;
Wiig and Reed, 1983). Thus, the increase in the CVP ofthe vessels
draining the tumour could lead to a further increase in the tumour
MVP and IFP.
Pressure gradients have been evaluated in the normal brain and
after inducing lesions in the cortex. In two studies in normal brain,
no pressure gradients were found between CSF and the grey or
white matter (Poll et al, 1972; Wiig and Reed, 1983). Reulen and
collaborators (Reulen and Kreysch, 1973; Reulen et al, 1977)
measured pressures in the normal brain and in a cold lesion model
of the cortex. Under normal conditions, they measured higher
pressures in the CSF than in the white matter, and the lesion in the
cortex induced higher pressures close to the lesion compared with
the ventricles and distant sites in the white matter. Our results
show that, in F98 gliomas with volumes ofapproximately 10 mm3,
there is a pressure gradient from the tumour to the cortex. At
tumour volumes > 16 mm3, which is approximately 1% of the
brain volume of a rat, the IFP equilibrates between the tumour and
the surrounding cortex (Figure 2 and Table 1). The decrease in
pressure gradient from the tumour to the cortex is probably due to
fluid filtration from tumour vessels. With increasing tumour size,
the number of tumour vessels with high filtration rates increases
thus surpassing the drainage capacity ofthe surrounding brain and
thus inducing the pressure build-up. The pressure equilibration
between the tumour and the surrounding tissue decreases the filtra-
tion of fluid towards an equilibrium that determines the extent of
peritumoral oedema (Reulen et al, 1990). Pressure equilibration
could be favoured by the absence of lymphatics in the cortex and
the high resistance to bulk flow offered by the tortuous organiza-
tion of the interstitial space of the grey matter (Fenstermacher,
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1984). In contrast, we have shown that the IFP was uniform
throughout subcutaneous tumours and dropped steeply at the
tumour-skin interface (Boucher et al, 1990).
DMF treatment and hypocapnia
DMF treatment significantly decreased the IFP in the cortex and in
F98 and R3230AC tumours localized in the parenchyma. Because
of the larger pressure drop in the brain tissue, an IFP gradient was
induced in both tumour types between the tumour and the
surrounding cortex (Table 2). A pressure gradient was also
induced by DMF treatment between F98 tumours and the
ventricle, however no pressure gradient was found between
R3230AC tumours and the ventricle. The larger tumour volume in
R3230AC (mean volume 127 mm3) compared with F98 tumours
(mean volume 30.0 mm3) could be responsible for the absence of
pressure difference between the tumour and the ventricle. Because
of the large size and thus close proximity to the ventricle, the
R3230AC tumours could compress or obstruct the ventricle.
The presence of pressure gradients between the tumour and
cortex or the tumour and ventricles in animals with small F98
tumours or following DMF treatment will favour the drainage of
fluids and plasma proteins by bulk flow. In a cold-lesion model in
the cortex, Reulen et al (1978) demonstrated that the clearance of
water and albumin via the ventricles was significantly increased
by experimentally inducing a pressure gradient between the cortex
and the ventricles. The CSF is a significant pathway for the clear-
ance ofplasma proteins; 87% of the radioactive albumin cleared
from the white matter can escape via the CSF system (Marmarou
et al, 1994). The pressure gradients between the tumour and the
cortex favours the drainage ofperitumoral fluid via the subarach-
noid space (Table 2). Arbit et al (1994) measured, in patients
treated with dexamethasone alone (E Arbit, personal communica-
tion), a pressure gradient of 6.5 mmHg from the centre of brain
tumours to the cortex. However, our measurements in patients
with brain tumours did not reveal an IFP difference between the
tumour and the surrounding brain, which could be due to the low
IFP in the tumours and the limited number ofpatients in which the
IFP was measured in both spaces.
The reduction in intraparenchymal and tumour IFP as well as in
CSFP by DMF treatment and hypocapnia can be explained by the
following mechanisms: (1) a reduction in vascular volume and
pressure; (2) an increased resistance to the transvascularpassage of
water and serum proteins; (3) the osmotic or oncotic shifts offluid
from the interstitial space to blood; and 4) a reduction in CSF
production. In the present study, the exact role of dexamethasone,
mannitol and furosemide in the reduction of intracranial pressure
or tumour IFP is impossible to define precisely as the three agents
were used concomitantly. Furthermore, it is probable that each
agent has more than one mechanism of action. Dexamethasone
could reduce the tumour IFP and the intracranial pressure by
decreasing the vascular permeability of tumour vessels or by
reducing the vascular volume of the brain and brain tumours
(Leenders et al, 1985; Reichman et al, 1986; Nakagawa et al, 1988;
Neuwelt et al, 1993). Systemic infusions of mannitol can induce
significant decreases in CSFP as well as in the water content ofthe
normal brain and brain tumours (Bell et al, 1987; Ravussin et al,
1988; Hartwell and Sutton, 1993). The decrease in intracranial
pressure induced by mannitol has been associated with osmotic
shifts of water from the interstitial space to blood. Muizelaar et al
(1983) have also proposed that the arteriolar vasoconstriction
resulting from the systemic haemodilution induced by mannitol
could reduce the cerebral blood volume and thus decrease CSFP.
The diuretic furosemide can decrease intracranial pressure and
potentiate the reduction in intracranial pressure with mannitol
(Pollay et al, 1983; Albright et al, 1984). Reductions in intracranial
pressure with furosemide may result from the inhibition of the
reabsorption of water and sodium chloride by kidney tubules
and/or the inhibition ofCSF formation (McCarthy and Reed, 1974;
Pollay et al, 1983). Reductions in CSF formation have also been
demonstrated following treatment with mannitol and dexametha-
sone (Weiss and Nulsen, 1970; Donato et al., 1994).
DMF treatment and hypocapnia significantly reduced the
intracranial pressure as well as the IFP in intraparenchymal
tumours and R3230AC on the pial surface (Table 1). The reduction
in intracranial pressure suggests that the decrease in the tumour
MVP and IFP could be subsequent to a reduction in the CVP ofthe
vessels draining the tumour. As mentioned previously, at low and
high values of intracranial pressure the CVP is always kept
slightly higher than the CSFP (Yada et al, 1973; Luce et al, 1982;
Wiig and Reed, 1983). Wiig and Reed (1983) have shown that the
CVP and CSFP change in parallel during the modulation of the
Paco2. In the present study in animals that were not treated with
DMF, decreasing the Paco2 from a mean of 36 mmHg to 24
mmHg significantly reduced the IFP in R3230AC on the pial
surface and the CSFP by 33% and 45% respectively. Thus in
animals that were treated with DMF and hypocapnia a portion of
the decrease in tumour MVP and IFP was probably as a result of
the decrease in CVP induced by the low Paco2. Reductions in
brain volume (e.g. decrease in peritumoral oedema) could also
lead to a decrease in CVP and in tumourIFP, especially ifthe cere-
bral venous vessels are compressed by the expansion ofthe brain.
The reduction in the IFP of intraparenchymal tumours and
R3230AC on the pial surface could also result from a decrease in
water content induced by oncotic and osmotic gradients across
tumour vessels. Hyperosmolar solutions have been shown to
reduce the water content of brain tumours in patients and in a
rodent model (Bell et al, 1987; Hansen et al, 1994). Hansen et al
(1994) found with hypertonic sodium chloride a significant reduc-
tion in the water content of a brain glioma in the rat, which was
impermeable to Evans blue, however hypertonic sodium chloride
was not able to reduce the water content of a cold induced brain
lesion permeable to Evans blue. The accumulation of Evans blue
in treated and non-treated R3230AC and F98 tumours suggests
that mannitol could equilibrate fairly rapidly across the microvas-
cular wall, thus preventing the establishment of an effective
osmotic gradient in those tumours. However, from the qualitative
evaluation of the extravasation of Evans blue, it is impossible to
determine ifthe oncotic gradient was increased by DMFtreatment.
As dexamethasone can reduce the accumulation of macromole-
cules in brain tumours (Reichman et al, 1986; Neuwelt et al,
1993), the oncotic gradient could be modified by DMF treatment.
IFP in intracranial tumours in patients
In the present study, the mean IFP in brain tumours in patients was
2.0 mmHg, and Arbit et al (1994) recently reported a mean IFP of
7.2 mmHg by averaging the IFPs for meningiomas, glioblastomas
and brain metastases. We speculated that the low IFP in brain
tumours in patients was because of DMF treatment, hypocapnia
and opening ofthe intracranial cavity as in normal human subjects
CSFP can vary between 6 and 17.5 mmHg, with a mean around
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10 mmHg (Gilland et al, 1974; Corbett and Mehta, 1983), and
untreated patients with brain tumours can have mean CSFPs
varying between 24 and 33 mmHg depending on the studies
(Kullberg and West, 1965; Miller and Leech, 1975; Alberti et al,
1978). Our experimental results confirm that the IFP in tumours on
the pial surface and in the parenchyma is elevated, and that DMF
treatment and hypocapnia can reduce significantly the IFP in
intracranial tumours (Table 1). As it was impossible to measure the
intratumoral pressure in a control group or before the opening of
the intracranial cavity, it is not possible to conclude, in patients,
that the low intratumoral IFP resulted exclusively from DMF treat-
ment and hypocapnia. Fluid loss from the intracranial cavity can
significantly reduce the CSFP (Lundberg and West, 1965; Gilland
et al, 1974). It is also possible that, because of the lower vascular
permeability of some brain tumours (Yuan et al, 1994), the IFP
could be low or similar to the CSFP, especially in turnours not
influenced by growth in a confined space. However, even in a
tumour with a low vascular permeability, the pressure could be
elevated as a result ofequilibration with the intracranial pressure.
In summary, the results demonstrate that, similar to some
peripheral tumours, the IFP of R3230AC on the pial surface
increased with tumour size and the tumour MVP was similar to the
IFP. In contrast to subcutaneous tumours, the IFP did not decrease
in the periphery ofthe larger tumours in the cortex; the pressure in
the surrounding cortex and in the tumour were equal. Treatment
with DMF significantly decreased the IFP ofbrain tumours and the
intracranial pressure, and induced pressure gradients between the
tumours and the cortex. The low IFP values in intracranial tumours
in patients are due in part to DMF treatment and hypocapnia.
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